Quest Diagnostics delivered a strong finish to 2025, generating double-digit growth in revenues and earnings per share for the full year. Q4 revenue reached $2.81 billion, up 7.1% year-over-year, with adjusted EPS of $2.42. Growth was driven by robust demand in advanced diagnostics (Alzheimer’s, autoimmune, oncology) and a rapidly expanding consumer channel, which generated nearly $250 million in revenue in 2025. Strategic collaborations with Fresenius Medical Care and Corewell Health are scaling, contributing to volume growth despite initial margin dilution. For 2026, management projects continued confidence with revenue guidance of $11.7 billion to $11.82 billion (6% to 7.1% growth) and adjusted EPS of $10.50 to $10.70, positioning the company as a 'premier lab engine' in the wellness industry.
| Metric | Value | Change |
|---|---|---|
| Q4 Revenue | $2.81 billion | +7.1% |
| Q4 Organic Revenue Growth | 6.4% | N/A |
| Q4 Adjusted EPS | $2.42 | +8.5% |
| Q4 Volume Growth | 8.5% | N/A |
| 2026 Revenue Guidance | $11.70 - $11.82 billion | +6.0% to 7.1% |
| 2026 Adjusted EPS Guidance | $10.50 - $10.70 | N/A |
| Consumer Revenue (2025) | ~$250 million | >20% |
Management is heavily prioritizing the Consumer Initiated Testing and Wellness channel. This segment delivered nearly $250 million in revenue in 2025, exceeding 20% growth. By partnering with wearable companies like WHOOP and Oura, and expanding questhealth.com, Quest is capturing the 'prevention' market. This strategy is accretive to margins as it involves no denials or bad debt, contrasting with traditional insurance-based testing.
The Corewell Health and Fresenius Medical Care partnerships represent a strategic shift toward high-volume, integrated hospital partnerships. While the Corewell CoLab solution adds ~$250 million in organic revenue for 2026, it comes at 'low single-digit margins' initially. Management views this as a long-term play to secure market share and volume, with margins expected to normalize to 'low teens' by 2027.
Quest is leveraging 'Advanced Diagnostics' to drive 'test per requisition' growth. Innovations like the Analyzer (autoimmune), AD-Detect (Alzheimer’s), and Haystack/Flow MRD (oncology) are seeing double-digit growth. This shift in mix toward higher-value, specialized testing helps offset pricing pressure and volume fluctuations in routine testing.
Operational efficiency remains a core pillar, driven by the 'INFIGURATE' program and AI implementation. The company achieved 3% cost savings in 2025 and is deploying AI agents to reduce logistics calls by 50%. This focus on productivity is essential to fund 'Project Nova,' a major modernization initiative that will dilute EPS by $0.25 in 2026 but is critical for long-term scalability.
Margin expansion faces significant headwinds in 2026 despite strong revenue growth. The ramp of the Corewell and Fresenius contracts carries lower initial margins ('low single-digits' for Corewell). Additionally, 'Project Nova' will dilute EPS by approximately $0.25 due to increased investment spend. An extra payroll cycle in 2026 (53 weeks) compared to 2025 will also impact cash flow and operating income comparisons.
The PAMA (Protecting Access to Medicare Act) situation remains a lingering threat despite a one-year delay to 2026. Management warned that the legislation's 'structural flaws' remain, specifically the reliance on self-reported data from thousands of labs. If the data collection in 2025 is not representative, it could trigger 'excessive rate cuts' in the future, posing a risk to reimbursement rates.
Severe weather in January 2026 created a 'greater headwind' than the prior year, impacting Q1 results. While management believes the volume will recover ('general health and wellness types of work always come back'), the unpredictability of weather introduces volatility to the start of the year, potentially skewing quarterly comparisons.
Revenue per requisition declined by 0.1% in Q4. While management attributes this to the mix shift toward lower-revenue-per-requisition contracts like Fresenius and Corewell, ex-these relationships, growth was only 3%. This suggests that pricing power remains constrained and growth is heavily volume-dependent rather than price-driven.
Overall: Management exhibited a high level of confidence and discipline throughout the call. Jim Davis emphasized 'diligent execution' and 'strong fundamentals,' while Sam Samad provided detailed financial bridges, signaling transparency. The tone remained optimistic regarding long-term demographic trends and innovation, though they acknowledged near-term headwinds like weather and startup costs with pragmatic language.
Confidence: HIGH - Management provided specific guidance ranges, detailed growth drivers by vertical, and openly discussed the margin cadence of new business lines. Their willingness to quantify dilution from Project Nova and Corewell suggests strong command of the business.
$11.7 billion to $11.82 billion (6% to 7.1% growth)
$9.45 to $9.65
$10.50 to $10.70
Approximately $1.75 billion
Approximately $550 million
Hedging & Uncertainty: Management used specific, concrete language regarding financial results and guidance, minimizing hedging in the prepared remarks. However, hedging appeared when discussing external factors like PAMA legislation ('I am not sure the other 10,000 labs... are prepared to report') and weather recovery ('whether it is 30%, 40%, it is hard to predict'). They also used temporal qualifiers regarding the Corewell margin ramp, noting it would be dilutive in 2026 but improve 'later in 2027 and beyond.' This suggests confidence in internal execution but caution regarding regulatory and environmental variables.
We greatly appreciate Congress for recognizing the need to reform PAMA... However, these steps do not fix PAMA’s structural flaws. - Jim Davis, CEO
The general health and wellness types of work always come back to us. - Jim Davis, CEO
Operating margin is expected to increase in 2026 versus 2025. - Sam Samad, CFO
We are focused on connecting everyone, from clinicians to consumers, to illuminate a path to better health. - Jim Davis, CEO
It is a high-volume business... still very profitable, based on the fact that we do not do draws. - Jim Davis, CEO
Analyst Sentiment: Analysts were highly engaged, focusing heavily on the sustainability of growth rates and the specific mechanics of the new hospital partnerships (Corewell/Fresenius). There was clear interest in understanding the margin bridge and the dilutive effects of Project Nova.
Management Responses: Management was detailed and responsive, breaking down organic growth ex-Fresenius/Corewell (4.1%) to prove underlying strength. They provided specific timelines for margin improvements on new contracts and quantified the weather impact, demonstrating a strong grasp of the business drivers.
Analysts probed the 'quality' of the 6.4% organic growth, asking how much was share gains vs. market growth. Management confirmed share gains, specifically citing the reinstatement of contracts with Elevance and Sentara.
The margin impact of the Corewell and Fresenius partnerships was a major topic. Management clarified that while these deals are currently dilutive to margins, they are strategically important for volume and will improve over time.
Questions regarding the consumer segment focused on the sustainability of >20% growth. Management pointed to renewal rates in subscription partnerships and the 'run-rate' of questhealth.com as evidence of durability.
The PAMA legislation delay was discussed, with management emphasizing the need for the 'RESULTS Act' to fix long-term structural issues rather than just temporary delays.
Quest Diagnostics is executing a successful pivot from a low-margin commodity player to a diversified healthcare insights leader. The double-digit EPS growth and strong 2026 guidance underscore the resilience of the business model. Key growth drivers, including the consumer channel (>20% growth) and advanced diagnostics (Alzheimer's, Oncology), are gaining traction and improving the test mix. While near-term margins face pressure from Project Nova and the ramp-up of the Corewell partnership, these are investments in future scalability and market share. The company's strong free cash flow generation ($1.89B in 2025) provides ample capital for dividends, M&A, and internal investment, making DGX a compelling holding for stable, growth-oriented income investors.
Congress enacted a one-year delay to PAMA rate cuts, providing short-term relief. However, management warns that the structural flaws of the legislation remain, creating long-term uncertainty for reimbursement rates if the 'RESULTS Act' is not passed.
Management observes 'enduring interest' in preventative health and wellness, driven by favorable demographic trends and an aging population. This supports sustained volume growth in core testing and high-growth areas like cardiovascular and diabetes monitoring.
There is a significant shift toward consumer-initiated testing and wearables. Patients are increasingly seeking 'prevention' rather than waiting for symptoms, driving demand for Quest's consumer platform and partnerships with companies like WHOOP and Oura.